Identification of a novel "almost neutral" μ-opioid receptor antagonist in CHO cells expressing the cloned human μ-opioid receptor

Synapse

Volumn 64, Issue 4, 2010, Pages 280-288

  Sally, Elliott J ^a   Xu, Heng ^a   Dersch, Christina M ^a   Hsin, Ling Wei ^b   Chang, Li Te ^b   Prisinzano, Thomas E ^c   Simpson, Denise S ^c   Giuvelis, Denise ^d   Rice, Kenner C ^a   Jacobson, Arthur E ^a   Cheng, Kejun ^a   Bilsky, Edward J ^d   Rothman, Richard B ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c UNIVERSITY OF KANSAS   (United States)

^d UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

G proteins; Herkinorin; Inverse agonist; Neutral antagonist; Opioid receptor

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; KC 2 009; LTC 274; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALTREXOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANALGESICS, OPIOID; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FURANS; GENE EXPRESSION REGULATION; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; NARCOTIC ANTAGONISTS; PROTEIN BINDING; PYRONES; RECEPTORS, OPIOID, MU; SULFUR ISOTOPES;

EID: 73449114609     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20723     Document Type: Article

References (21)

1. Bilsky EJ, Bernstein RN, Wang Z, Sadee W, Porreca F. 1996. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 277:484-490.
2. Brandt GE, Schmidt MD, Prisinzano TE, Blagg BS. 2008. Gedunin, a novel hsp90 inhibitor: Semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem 51:6495-6502.
3. Ciganek E. 1981. 2,3,4,4a,5,6,7,7a-Octahydro-1H-benzofuro[3,2-e] isoquinoline: A newmorphine fragment. J Am Chem Soc 103:6261-6262.
4. Costa T, Herz A. 1989. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
5. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, Bohn LM. 2007. An opioid agonist that does not induce μ-opioid receptor b-arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557.
6. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE. 2005. Neoclerodane diterpenes as a novel scaffold for l opioid receptor ligands. J Med Chem48:4765-4771.
7. Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC. 2007. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. J Med Chem 50:3765-3776.
8. Kenakin T. 2004. Efficacy as a vector: The relative prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
9. Kieffer BL, Evans CJ. 2009. Opioid receptors: From binding sites to visible molecules in vivo. Neuropharmacology 56(Suppl 1):205-212.
10. Kurimura M, Liu H, Sulima A, Hashimoto A, Przybyl AK, Ohshima E, Kodato S, Deschamps JR, Dersch CM, Rothman RB, Lee YS, Jacobson AE, Rice KC. 2008. Probes for narcotic receptor mediated phenomena, Part 37: Synthesis and opioid binding affinity of the final pair of oxide-bridged phenylmorphans, the ortho- and para-b-isomers and their N-phenethyl analogues, and the synthesis of the N-phenethyl analogues of the ortho- and para-d-isomers. J Med Chem 51:7866-7881.
11. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadee W, Bilsky EJ. 2005. In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 313:1150-1162.
12. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. 2002. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939.
13. Rothman RB, Murphy DL, Xu H, Godin JA, Dersch CM, Partilla JS, Tidgewell K, Schmidt M, Prisinzano TE. 2007. Salvinorin A: Allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther 320:801-810.
14. Sadee W, Wang D, Bilsky EJ. 2005. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci 76:1427-1437.
15. Samama P, Pei G, Costa T, Cotecchia S, Lefkowitz RJ. 1994. Negative antagonists promote an inactive conformation of the β 2-adre-nergic receptor. Mol Pharmacol 45:390-394.
16. Wang D, Raehal KM, Bilsky EJ, Sadee W. 2001. Inverse agonists and neutral antagonists at μ opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence. J Neurochem 77:1590-1600.
17. Wang D, Sun X, Sadee W. 2007. Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321:544-552.
18. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ. 2001. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu agonist/delta antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther 297:597-605.
19. Xu H, Lu YF, Thomas JB, Carroll FI, Rice KC, Rothman RB. 2001. Opioid peptide receptor studies, Part 15: Relative efficacy of 4-[(N-allyl-3- methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide and related compounds at the cloned human delta-opioid receptor. Synapse 40:269-274.
20. Xu H, Wang X, Wang J, Rothman RB. 2004. Opioid peptide receptor studies, Part 17: Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned mu opioid receptor. Synapse 52:209-217.
21. Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, Rothman RB. 2007. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) μ-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 61:166-175.